← Back to Search

HSP90 inhibitor

PU-H71 for Myelofibrosis

Phase 1
Waitlist Available
Research Sponsored by Samus Therapeutics, Inc.
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Subject is willing and able to provide written informed consent before any study-specific procedures are performed.
Subject is willing to comply with all study procedures and restrictions.
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 24 weeks
Awards & highlights

Study Summary

This study is evaluating whether a drug may help patients with a rare blood disorder.

Eligible Conditions
  • Myelofibrosis
  • Primary Myelofibrosis

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~24 weeks
This trial's timeline: 3 weeks for screening, Varies for treatment, and 24 weeks for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Assess Safety and Tolerability of PU-H71
Assess Safety, Tolerability and Pharmacokinetics of PU-H71
Assess treatment response of PU H71

Trial Design

4Treatment groups
Experimental Treatment
Group I: Oral -100 mgExperimental Treatment1 Intervention
PU-H71 (a small molecule purine-scaffold epichaperome inhibitor selective for stress-induced HSP90 in epichaperomes).
Group II: Oral - 50mgExperimental Treatment1 Intervention
PU-H71 (a small molecule purine-scaffold epichaperome inhibitor selective for stress-induced HSP90 in epichaperomes).
Group III: Oral - 300 mgExperimental Treatment1 Intervention
PU-H71 (a small molecule purine-scaffold epichaperome inhibitor selective for stress-induced HSP90 in epichaperomes).
Group IV: Oral - 200 mgExperimental Treatment1 Intervention
PU-H71 (a small molecule purine-scaffold epichaperome inhibitor selective for stress-induced HSP90 in epichaperomes).
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
PU-H71
Not yet FDA approved

Find a Location

Who is running the clinical trial?

Samus Therapeutics, Inc.Lead Sponsor
8 Previous Clinical Trials
72 Total Patients Enrolled
Michael Silverman, M.D.Study DirectorSamus Therapeutics
Hagop Youssoufian, M.D.Study DirectorSamus Therapeutics

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
~2 spots leftby Mar 2025